Development and in vivo evaluation of 18 F-labeled PET tracers covalently targeting KRAS-G12C for noninvasive cancer diagnosis and therapy monitoring
Theranostics · 2026
DOI: 10.7150/thno.123741 ↗At a glance
Journal article in Theranostics, 2026. Written by Michael Willmann and 9 co-authors. Institution: Department of Nuclear Medicine, Hannover Medical School, Germany. Major MEDLINE topics: Proto-Oncogene Proteins p21(ras), Positron-Emission Tomography, Fluorine Radioisotopes. Cited 1 times so far (Crossref). The full text is freely available in PubMed Central.
Abstract (original language)
RATIONALE: Mutations in the KRAS gene are some of the most frequent drivers in cancer, including non-small cell lung and colorectal cancer. Covalent inhibitors such as adagrasib, targeting the inactive, GDP-bound form of KRAS-G12C, have shown clinical efficacy but patient selection still depends on invasive biopsies. This study aimed to develop novel fluorine-18 labeled KRAS-G12C inhibitors for noninvasive positron emission tomography (PET) imaging of KRAS mutation status. METHODS: Three KRAS-G12C inhibitors were synthesized by modifying the adagrasib scaffold to allow for radiofluorination. Compounds were evaluated for target affinity and specificity using pERK inhibition assays in KRAS-G12C positive MiaPaCa-2 cells and KRAS protein binding assays. Finally, in vivo PET imaging and biodistribution studies were performed in MiaPaCa-2 xenograft-bearing mice under baseline and blocking conditions to assess tumor uptake, specificity, and tracer pharmacokinetics. RESULTS: In µPET, the tracers showed distinct tumor uptake and biodistribution profiles. Among them, [18F]KRAS490 demonstrated the most promising characteristics, with clear tumor accumulation that was significantly reduced under blocking conditions, indicating specific target binding. In contrast, [18F]KRAS8125 and [18F]KRAS3776 showed limited or non-replaceable tumor uptake. The tracers showed varied clearance patterns, with [18F]KRAS490 showing combined hepatobiliary and renal clearance. Notably, [18F]KRAS490 also entered the brain, suggesting the potential for central nervous system imaging. CONCLUSIONS: [18F]KRAS490 showed specific, blockable tumor uptake and favorable pharmacokinetics, making it a promising tracer for noninvasive imaging of KRAS-G12C mutant tumors. Its ability to penetrate the CNS supports potential application in imaging both peripheral and brain lesions.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Nuclear Medicine, Hannover Medical School, Germany.
- Merck Healthcare KGaA, Darmstadt, Germany.
Cite
APA
Willmann, M., Bankstahl, J. P., Bengel, F. M., Drechsler, C., Esdar, C., Gläser, K., Lopez, A. U., Ross, T., Schieferstein, H., & Ross, T. L. (2026). Development and in vivo evaluation of 18 F-labeled PET tracers covalently targeting KRAS-G12C for noninvasive cancer diagnosis and therapy monitoring. Theranostics. https://doi.org/10.7150/thno.123741
Vancouver
Willmann M, Bankstahl JP, Bengel FM, Drechsler C, Esdar C, Gläser K, et al. Development and in vivo evaluation of 18 F-labeled PET tracers covalently targeting KRAS-G12C for noninvasive cancer diagnosis and therapy monitoring. Theranostics. 2026. doi:10.7150/thno.123741
BibTeX
@article{Willmann2026,
author = {Willmann, Michael and Bankstahl, Jens P and Bengel, Frank M and Drechsler, Christine and Esdar, Christina and Gläser, Kathrin and Lopez, Andrea U and Ross, Tatjana and Schieferstein, Hanno and Ross, Tobias L},
title = {Development and in vivo evaluation of 18 F-labeled PET tracers covalently targeting KRAS-G12C for noninvasive cancer diagnosis and therapy monitoring},
journal = {Theranostics},
year = {2026},
doi = {10.7150/thno.123741}
}
EUVIMED